Literature DB >> 10527683

Genotype-phenotype correlations in disorders of peroxisome biogenesis.

H W Moser1.   

Abstract

Genetically determined human peroxisomal disorders are subdivided into two major categories: disorders of peroxisome biogenesis (PBD), in which the organelle is not formed normally, and those that involve a single peroxisomal enzyme. Twelve PBD have been identified, and the molecular defects have been defined in 10. All involve defects in the import of proteins into the organelle. Factors required for this import are now referred to as peroxins (PEX) and form the basis of a new and preferred classification system. The PBD are associated with four clinical phenotypes, named before their association with the organelle was recognized: Zellweger syndrome (ZS), neonatal adrenoleukodystrophy (NALD), infantile Refsum disease (IRD), and rhizomelic chondrodysplasia punctata (RCDP). The first three are associated with 9 of the 10 PEX defects that have been defined so far, and represent a clinical continuum with variant severity, with ZS the most severe, NALD intermediate, and IRD the least severe. RCDP is associated with PEX7. Genotype-phenotype correlations are complicated by the fact that the clinical manifestations of the ZS-NALD-IRD continuum can be mimicked by disorders that affect single enzymes of peroxisomal fatty acid oxidation, and PEX7 by disorders of plasmalogen synthesis enzymes. Furthermore, clinical manifestations of each of the PEX disorders may vary. Phenotypic expression varies with the nature of the mutation, the milder phenotypes being associated with mutations that do not abolish function completely, or with mosaicism. Definition of the molecular defects is of great value for genetic counseling and may be of aid in establishing prognosis. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10527683     DOI: 10.1006/mgme.1999.2926

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  20 in total

1.  The peroxisomal membrane protein Pex13p shows a novel mode of SH3 interaction.

Authors:  P Barnett; G Bottger; A T Klein; H F Tabak; B Distel
Journal:  EMBO J       Date:  2000-12-01       Impact factor: 11.598

2.  PEX11alpha is required for peroxisome proliferation in response to 4-phenylbutyrate but is dispensable for peroxisome proliferator-activated receptor alpha-mediated peroxisome proliferation.

Authors:  Xiaoling Li; Eveline Baumgart; Gao-Xiang Dong; James C Morrell; Gerardo Jimenez-Sanchez; David Valle; Kirby D Smith; Stephen J Gould
Journal:  Mol Cell Biol       Date:  2002-12       Impact factor: 4.272

3.  Defective peroxisome membrane synthesis due to mutations in human PEX3 causes Zellweger syndrome, complementation group G.

Authors:  A C Muntau; P U Mayerhofer; B C Paton; S Kammerer; A A Roscher
Journal:  Am J Hum Genet       Date:  2000-08-24       Impact factor: 11.025

4.  Contiguous deletion of the X-linked adrenoleukodystrophy gene (ABCD1) and DXS1357E: a novel neonatal phenotype similar to peroxisomal biogenesis disorders.

Authors:  Deyanira Corzo; William Gibson; Kisha Johnson; Grant Mitchell; Guy LePage; Gerald F Cox; Robin Casey; Carolyn Zeiss; Heidi Tyson; Garry R Cutting; Gerald V Raymond; Kirby D Smith; Paul A Watkins; Ann B Moser; Hugo W Moser; Steven J Steinberg
Journal:  Am J Hum Genet       Date:  2002-04-29       Impact factor: 11.025

5.  Nonsense suppressor therapies rescue peroxisome lipid metabolism and assembly in cells from patients with specific PEX gene mutations.

Authors:  Patricia K Dranchak; Erminia Di Pietro; Ann Snowden; Nathan Oesch; Nancy E Braverman; Steven J Steinberg; Joseph G Hacia
Journal:  J Cell Biochem       Date:  2011-05       Impact factor: 4.429

6.  Disorders of peroxisome biogenesis due to mutations in PEX1: phenotypes and PEX1 protein levels.

Authors:  C Walter; J Gootjes; P A Mooijer; H Portsteffen; C Klein; H R Waterham; P G Barth; J T Epplen; W H Kunau; R J Wanders; G Dodt
Journal:  Am J Hum Genet       Date:  2001-06-01       Impact factor: 11.025

7.  PEX11 beta deficiency is lethal and impairs neuronal migration but does not abrogate peroxisome function.

Authors:  Xiaoling Li; Eveline Baumgart; James C Morrell; Gerardo Jimenez-Sanchez; David Valle; Stephen J Gould
Journal:  Mol Cell Biol       Date:  2002-06       Impact factor: 4.272

8.  A PEX6-defective peroxisomal biogenesis disorder with severe phenotype in an infant, versus mild phenotype resembling Usher syndrome in the affected parents.

Authors:  Annick Raas-Rothschild; Ronald J A Wanders; Petra A W Mooijer; Jeannette Gootjes; Hans R Waterham; Alisa Gutman; Yasuyuki Suzuki; Nobuyuki Shimozawa; Naomi Kondo; Gideon Eshel; Marc Espeel; Frank Roels; Stanley H Korman
Journal:  Am J Hum Genet       Date:  2002-02-28       Impact factor: 11.025

Review 9.  From peroxisomal disorders to common neurodegenerative diseases - the role of ether phospholipids in the nervous system.

Authors:  Fabian Dorninger; Sonja Forss-Petter; Johannes Berger
Journal:  FEBS Lett       Date:  2017-09-07       Impact factor: 4.124

10.  Drosophila carrying pex3 or pex16 mutations are models of Zellweger syndrome that reflect its symptoms associated with the absence of peroxisomes.

Authors:  Minoru Nakayama; Hiroyasu Sato; Takayuki Okuda; Nao Fujisawa; Nozomu Kono; Hiroyuki Arai; Emiko Suzuki; Masato Umeda; Hiroyuki O Ishikawa; Kenji Matsuno
Journal:  PLoS One       Date:  2011-08-03       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.